Antipsychotics as antidepressants

  title={Antipsychotics as antidepressants},
  author={Rona Jeannie Roberts and Kavita Lohano and Rif S El-Mallakh},
  journal={Asia‐Pacific Psychiatry},
  pages={179 - 188}
Three second‐generation antipsychotic (SGA) agents have received FDA approval for adjunctive treatment, to antidepressant, of major depressive disorder: quetiapine, aripiprazole, and olanzapine. Additionally, quetiapine and lurasidone have been approved for the treatment of bipolar depression. There are data suggesting that quetiapine is effective for major depressive disorder as monotherapy. These agents are effective for depression only at subantipsychotic doses. Receptor profiles predict… 
The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders
Contrary to SAD and PD, this review found evidence for the use of second-generation antipsychotics in GAD and OCD, and first-generation anti-anxiety drugs cannot be recommended in anxiety disorders and OCD.
Advances in the psychopharmacotherapy of bipolar disorder type I
Recent effectiveness studies continue to confirm the superiority of lithium and other mood stabilizers in the management of bipolar illness for both psychiatric and medical outcomes, reaffirming their role as foundational treatments in the Management of type I bipolar disorder.
Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials
Overall, SGAs appear to offer favorable improvements in MADRS and YMRS scores vs. placebo, and additional original studies are required to allow more reliable and clinically definitive conclusions.
Different molecular targets, one purpose – treatment of depression
Abstract Although vast scientific progress has been made, the current pharmacotherapy of depression is still not fully effective. In adults, depressive disorders are among the most common diseases in
A retrospective naturalistic study on the psychopharmacological treatment of schizoaffective disorder
The role of antipsychotics as the essential psychopharmacological treatment for different symptoms of schizoaffective disorder is corroborate, however, the role of mood stabilizers, antidepressants or BZD is controversial and should be individually considered.
A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
The overall safety and tolerability of long-term LDX augmentation of antidepressant monotherapy was consistent with the profiles of the short-term antecedent studies, with no evidence of new safety signals.
Quetiapine reverses paclitaxel-induced neuropathic pain in mice: Role of alpha2- adrenergic receptors
Results indicate that quetiapine, when administered after nerve injury can reverse the expression of neuropathic pain and conclude that α2-adrenoceptors participate in the antinociceptive effects of quetuapine.
Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disoder: A Prospective Observational Study: Erratum.
The findings confirm the efficacy of quetiapine on depressive symptoms, and the available data support that quetuapine's antidepressant activity is mediated by the active metabolite norquetiapines.
Blood Gene Expression Profile Predicts Response to Antipsychotics
A four-gene blood expression profile to predict the response to antipsychotics in schizophrenia patients before treatment is shown and it is anticipated that this approach is a gateway to select the specific antipsychotic that will produce the best response to treatment for each specific patient.
Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews
This overview stipulates the effectiveness of lurasidone in the acute treatment of Type I bipolar depression overall, and recommendations for future research should include further controlled trials of extended duration.


Second-generation antipsychotics in major depressive disorder: update and clinical perspective
Both SGA monotherapy and adjunctive therapy showed greater efficacy in the treatment of MDD than placebo, but augmentation is more widely utilized in treatment-resistant depression.
Quetiapine: a review of its use in the management of bipolar depression.
In a randomized, double-blind, placebo-controlled trial, quetiapine maintenance therapy for up to 104 weeks was more efficacious than placebo or lithium in prolonging the time to recurrence of any mood event and of depression mood events, but not of hypomanic/manic events.
The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Ziprasidone targets the key hypothetical neurochemical disturbance in psychosis-excessive dopamine neurotransmission at dopamine D2 receptors in the mesolimbic pathway of the brain-presumably responsible for the positive symptoms of schizophrenia.
Adjunctive Low-Dose Aripiprazole With Standard-Dose Sertraline in Treating Fresh Major Depressive Disorder: A Randomized, Double-Blind, Controlled Study
The primitive data showed that adjunctive low-dose aripiprazole could augment the efficacy of regular-dose sertraline in fresh major depressive disorder.
Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression
  • J. Amsterdam
  • Psychology, Biology
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 1992
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.
Olanzapine/fluoxetine combination demonstrated rapid onset of antidepressant effect (within 7 days) compared to placebo that was sustained over 8 weeks of treatment in a sample of BD patients.
Atypical Antipsychotic Augmentation Strategies in the Context of Guideline-based Care for the Treatment of Major Depressive Disorder
There is a growing body of evidence that supports the use of atypical antipsychotics as augmentation agents for nonpsychotic unipolar major depressive disorder (MDD) in adults. Unfortunately, varying
Treating Generalized Anxiety Disorder With Second Generation Antipsychotics: A Systematic Review and Meta-Analysis
Existing data suggest that SGAs are not superior to placebo as augmentation for refractory GAD and quetiapine monotherapy is more efficacious than placebo for uncomplicated GAD, but issues with adverse effects and tolerability may limit its use.